4-[1-(3-bromo-4-hydroxyphenyl)-1-[4-[2-(3-bromo-4-hydroxyphenyl)propan-2-yl]phenyl]ethyl]-2-bromophenol | 209900-81-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: 4-[1-(3-bromo-4-hydroxyphenyl)-1-[4-[2-(3-bromo-4-hydroxyphenyl)propan-2-yl]phenyl]ethyl]-2-bromophenol
• 英文别名: 4-[1-[4-[1,1-Bis(3-bromo-4-hydroxy-phenyl)ethyl]phenyl]-1-methyl-ethyl]-2-bromo-phenol；4-[2-[4-[1,1-bis(3-bromo-4-hydroxyphenyl)ethyl]phenyl]propan-2-yl]-2-bromophenol
• CAS: 209900-81-2
• 化学式: C₂₉H₂₅Br₃O₃
• 分子量: 661.228
• InChiKey: DVHKXJQBUOUBPY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9.6
• 重原子数：
  35
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  60.7
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  α,α,α'-三(4-羟苯基)-1-乙基-4-异丙苯 在 N-溴代丁二酰亚胺(NBS) 、 三氟甲磺酸 作用下， 以 二氯甲烷 、 丙酮 、 乙腈 为溶剂， 反应 3.33h， 以88%的产率得到4-[1-(3-bromo-4-hydroxyphenyl)-1-[4-[2-(3-bromo-4-hydroxyphenyl)propan-2-yl]phenyl]ethyl]-2-bromophenol
  参考文献：
  名称：

  Structure-Based Discovery of Triphenylmethane Derivatives as Inhibitors of Hepatitis C Virus Helicase

  摘要：

  Hepatitis C virus nonstructural protein 3 (HCV NS3) helicase is believed to be essential for viral replication and has become an attractive target for the development of antiviral drugs. A fluorescence resonant energy transfer helicase assay was established for fast screening of putative inhibitors selected from virtual screening using the program DOCK. Soluble blue HT (1) was first identified as a novel HCV helicase inhibitor. Crystal structure of the NS3 helicase in complex with soluble blue HT shows that the inhibitor bears a significantly higher binding affinity mainly through a 4-sulfonatophenylaminophenyl group, and this is consistent with the activity assay. Subsequently, fragment-based searches were utilized to identify triphenylmethane derivatives for more potent inhibitors. Lead optimization resulted in a 3-bromo-4-hydroxyl substituted derivative 12 with an EC50 value of 2.72 mu M to Ava.5/Huh-7 cells and a lower cytotoxicity to parental Huh-7 cells (CC50 = 10.5 mu M), and it indeed suppressed HCV replication in the HCV replicon cells. Therefore, these inhibitors with structural novelty may serve as a useful scaffold for the discovery of new HCV NS3 helicase inhibitors.

  DOI：

  10.1021/jm8011905

文献信息

• ONCE DAILY TREATMENT OF HEPATITIS C WITH RIBAVIRIN AND TARIBAVIRIN
  申请人：KADMON PHARMACEUTICALS LLC

  公开号：US20140363396A1

  公开（公告）日：2014-12-11

  Hepatitis C is treated by administering once daily ribavirin, taribavirin, other derivatives or pharmaceutically acceptable salts thereof. Hepatitis C may also be treated by administering any of the foregoing compounds once daily in combination with interferon and/or direct-acting antivirals. Once daily dosage forms administered for treating hepatitis C may comprise between 800 mg and 1400 of ribavirin. Once daily dosage forms administered for treating hepatitis C may also comprise between 800 mg and 4000 mg of taribavirin.
• ANTI-VIRAL COMBINATION THERAPY
  申请人：KOYUNCU Emre

  公开号：US20150139949A1

  公开（公告）日：2015-05-21

  The present invention provides methods and compounds for treating viral infections using combinations modulators of an HCV-associated component and modulators of host cell enzymes. The present invention also provides methods and compounds for treating viral infections using combinations of modulators of host cell enzymes and other agents that work, at least in part by modulating hos factors.